CD34 and acute myeloid leukemia: Upon subdividing the CD34+ AML cells into ROS-low and ROS-high fractions, the authors showed that the AML CD34+ ROS-low cells exhibited higher levels of basal autophagy and decreased survival when treated with the inhibitor of autophagic lysosomal fusion, hydroxychloroquine [51].